Curis Lifesciences Ltd Financials
Company Logo

Curis Lifesciences Ltd Financial Statement

Curis Lifesciences Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

No Data Available

Curis Lifesciences Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue Annual49.13
Operating Expenses Annual39.60
Operating Profit Annual10.05
Interest Annual1.11
Depreciation0.67
Net Profit Annual6.11
Tax Annual2.16

Curis Lifesciences Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the Beginning0.42
Cash Flow from Operations-1.76
Cash Flow from Investing-0.02
Cash Flow from Financing1.67
Cash Flow at the End0.30

Curis Lifesciences Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
PBDIT Margin (%)20.46
PBIT Margin (%)19.09
PBT Margin (%)1.89
Net PROFIT Margin (%)12.44
Return On Networth / Equity (%)55.32
Return On Networth /Employed (%)34.13
Return On Assets (%)22.26
Total Debt / Equity (X)1.48
Asset Turnover Ratio (%)1.79

Curis Lifesciences Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets Annual10.99
Total Current Assets Annual31.29
Non Current Assets Annual11.24
Total Shareholders Funds Annual16.23
Total Assets Annual42.53

Curis Lifesciences Ltd Earning Calls

EPS (INR)

Expected

24.00

Reported

24.00

Surprise

0.00%

FAQS on Curis Lifesciences Ltd Financials

As of Nov 14, 2025, Curis Lifesciences Ltd has a market capitalization of - Cr. Value Research classifies it as a Micro-Cap company.

Yes, Curis Lifesciences Ltd is not with a debt-to-equity ratio of 2.82.

In FY 2024 , Curis Lifesciences Ltd recorded a total revenue of approximately 35.66 Cr marking a significant milestone in the company's financial performance.

Curis Lifesciences Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately NaN% and 0.2% annually, respectively..

Curis Lifesciences Ltd's current PE ratio is .

Curis Lifesciences Ltd's ROCE averaged 22.9% from the FY ending March 2022 to 2024, with a median of 17.7%. It peaked at 34.9% in March 2024, reflecting strong capital efficiency over the period..

Curis Lifesciences Ltd's latest EBIT is Rs. 8.08 Cr, surpassing the average EBIT of Rs. 4.59 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions